Neurim Pharmaceuticals is a drug discovery and development company. Its first approved drug, Circadin® – prolonged release melatonin for insomnia, has been commercially available in the EU since October, 2007

Learn More
Parkinson’s disease
To establish a leadership position in small molecule drug research and development, aimed at improving quality of life of the older patient. Read More

11 June 2009
Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients.

24 September 2007

Neurim Pharmaceuticals licenses Circadin®, a drug approved for the treatment of primary insomnia, to Lundbeck
06 July 2007
Nycomed to market Circadin® for primary insomnia
29 June 2007
An Authorisation valid throughout the European Union was issued by the EMEA for Circadin®
27 April 2007
Neurim Pharmaceuticals announce that Circadin® (prolonged-release melatonin) for Primary Insomnia is recommended for approval in the EU
26 April 2007
Summary of positive opinion for Circadin® (EMEA Press Release)





Copyright © Neurim Pharmaceuticals , Inc. All rights reserved.
Impresser Disclaimer Legal Site map